Shares of Derma Sciences Inc. (NASDAQ:DSCI) saw an uptick in trading volume on Thursday . 443,001 shares traded hands during trading, an increase of 554% from the previous session’s volume of 67,705 shares.The stock last traded at $4.85 and had previously closed at $4.31.

Separately, Zacks Investment Research cut shares of Derma Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Derma Sciences has a consensus rating of “Hold” and a consensus target price of $7.45.

The company’s 50 day moving average is $4.07 and its 200-day moving average is $3.61. The company’s market cap is $125.55 million.

Derma Sciences (NASDAQ:DSCI) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business earned $20.20 million during the quarter, compared to analyst estimates of $20.60 million. Equities analysts anticipate that Derma Sciences Inc. will post ($0.20) EPS for the current fiscal year.

A hedge fund recently raised its stake in Derma Sciences stock. Jennison Associates LLC raised its stake in Derma Sciences Inc. (NASDAQ:DSCI) by 22.9% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,407,506 shares of the company’s stock after buying an additional 261,818 shares during the period. Jennison Associates LLC owned about 5.45% of Derma Sciences worth $6,432,000 at the end of the most recent quarter.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.